ALK and angioimmunoblastic T-cell lymphoma: The 18-month PFS for PTCL-NOS versus ALK-negative versus AITL/THF was 35.1% (95% CI: 19.7–50.9) vs. 51.4% (95% CI: 28.4–70.4) vs. 56.4% (95% CI: 36.0–72.5), log-rank test p 0.149; the 18-months OS for PTCL-NOS vs. ALK-negative vs. AITL/THF was 67.6% (95% CI: 47.7–81.3) vs. 70.2% (95% CI: 45.1–85.4) vs. 81.5% (95% CI: 60.9–91.9), log-rank test p = 0.685.